Epratuzumab, designated as hLL 2, is a humanized IgG1 monoclonal antibody targeting CD22, a cell surface antigen expressed predominantly on B cells. This antibody functions not only as an immunomodulatory agent but also as a tumor-imaging agent due to its specific binding to CD22. Epratuzumab has demonstrated the ability to induce phosphorylation of CD22, which plays a critical role in the modulation of B cell signaling and function. The primary applications of Epratuzumab have been in the study of non-Hodgkin’s lymphomas (NHL) and various autoimmune diseases, where it has shown potential in modulating immune responses and providing diagnostic imaging insights.
Epratuzumab, designated as hLL 2, is a humanized IgG1 monoclonal antibody targeting CD22, a cell surface antigen expressed predominantly on B cells. This antibody functions not only as an immunomodulatory agent but also as a tumor-imaging agent due to its specific binding to CD22. Epratuzumab has demonstrated the ability to induce phosphorylation of CD22, which plays a critical role in the modulation of B cell signaling and function. The primary applications of Epratuzumab have been in the study of non-Hodgkin’s lymphomas (NHL) and various autoimmune diseases, where it has shown potential in modulating immune responses and providing diagnostic imaging insights.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
